Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm – A Randomized Pilot Study
Translational Vision Science & Technology · 22.08.2023 · 12 (8) · 17
DOI: 10.1167/tvst.12.8.17 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Translational Vision Science & Technology, erschienen am 22.08.2023. Verfasst von Rona Z Silkiss und 4 weiteren Autor:innen. Beteiligte Einrichtung: Silkiss Eye Surgery, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Blepharospasm, Cannabidiol, Botulinum Toxins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS.
Abstract (Originalsprache)
Purpose
The purpose of this study was to evaluate the safety and efficacy of low dose cannabidiol (CBD; Epidiolex) as adjunctive therapy for idiopathic adult-onset blepharospasm (BPS), as well as develop a novel objective assessment methodology to gauge response.
Methods
Prospective, randomized, double-masked, placebo-controlled crossover design of 6 months duration of 12 patients with BPS undergoing routine maximal botulinum toxin (BTX) therapy and experiencing breakthrough symptoms. Participants received their standard BTX every 3 months and were randomized to group A = CBD daily in cycle 1, followed by placebo in cycle 2 or group B = placebo followed by CBD. Videos recorded at days 0, 45, and 90 of each cycle were analyzed to quantify eyelid kinematics. The Jankovic Rating Scale (JRS) was used to provide a clinical rating.
Results
All 12 patients completed the study without adverse events. CBD decreased median eyelid closure amplitude by 19.1% (-1.66 mm, confidence interval [CI] = -3.19 to -0.14 mm, P = 0.03), decreased median eyelid closure duration by 15.8% (-18.35 ms, CI = -29.37 to -7.32 ms, P = 0.001), and increased the maximum eyelid closure velocity by 34.8% (-13.26 mm/ms, CI = -20.93 to -5.58 mm/ms, P = 0.001). The JRS showed a 0.5 reduction in severity and frequency, which was not statistically significant.
Conclusions
Low dose CBD was safely tolerated and improved several BPS kinematic parameters. The clinical scale suggested a direction of effect but may have been underpowered. Further studies are needed to better quantify the clinical relevance. Translational Relevance: This work describes a novel assessment methodology and therapeutic approach to bBPS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Silkiss Eye Surgery, San Francisco, CA, USA.
- VA Sierra Nevada Health Care System, Reno, NV, USA.
- The Department of Ophthalmology, California Pacific Medical Center, San Francisco, California, USA.
- University of California, San Francisco, San Francisco, CA, USA.
- Smith-Kettlewell Eye Research Institute, San Francisco, CA, USA.
Förderung
- NEI NIH HHS
Zitieren
APA
Silkiss, R. Z., Koppinger, J., Truong, T., Gibson, D., & Tyler, C. (2023). Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm – A Randomized Pilot Study. Translational Vision Science & Technology, 12(8), 17. https://doi.org/10.1167/tvst.12.8.17
Vancouver
Silkiss RZ, Koppinger J, Truong T, Gibson D, Tyler C. Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm – A Randomized Pilot Study. Translational Vision Science & Technology. 2023;12(8):17. doi:10.1167/tvst.12.8.17
BibTeX
@article{Silkiss2023,
author = {Silkiss, Rona Z and Koppinger, Jayson and Truong, Timothy and Gibson, David and Tyler, Christopher},
title = {Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm – A Randomized Pilot Study},
journal = {Translational Vision Science & Technology},
year = {2023},
volume = {12},
number = {8},
pages = {17},
doi = {10.1167/tvst.12.8.17}
}
EUVIMED